Skip to main content
PCRX
NASDAQ Life Sciences

派克拉回应激进投资者，强调战略进展和股东回报

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$22.83
Mkt Cap
$924.384M
52W Low
$18.8
52W High
$27.64
Market data snapshot near publication time

summarizeSummary

派克拉生物科学公司（Pacira BioSciences）发表声明，回应DOMA Perpetual Capital Management提名三名董事候选人加入其董事会的决定。该公司重申其“5x30战略”以创造价值，详细介绍了其成就，如2025年治疗250万名患者、EXPAREL销量增长6.2%、通过获得21项专利加强知识产权、实现创纪录的毛利率、推进两个二期临床项目以及在2025年执行1.5亿美元的股份回购。这一声明直接跟随了早些时候关于DOMA Perpetual呼吁更换CEO和提名董事的消息，标志着潜在的代理权斗争的正式开始。投资者将密切关注双方的进一步发展以及即将举行的2026年年度会议，因为结果可能会对公司的领导和战略方向产生重大影响。

在该公告发布时，PCRX的交易价格为$22.83，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.2亿。 52周交易区间为$18.80至$27.64。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed PCRX - Latest Insights

PCRX
Apr 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
EXPAREL Real-World Data Reveals Significant Opioid Reduction, Lower Medical Costs for Medicare Hip Patients
Sentiment: Positive
View Wiseek Article
PCRX
Apr 17, 2026, 4:15 PM EDT
Filing Type: PREC14A
Importance Score:
8
Pacira BioSciences Faces Contested Director Election and Seeks Approval for Significant Equity Plan Expansion Amidst Activist Pressure
Sentiment: Negative
View Wiseek Article
PCRX
Apr 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
New Data Shows Pacira's EXPAREL Lowers Healthcare Costs, Opioid Use in Outpatient Orthopedic Surgeries
Sentiment: Positive
View Wiseek Article
PCRX
Mar 12, 2026, 7:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement and Company Sale
Sentiment: Negative
View Wiseek Article
PCRX
Mar 11, 2026, 5:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Pacira Counters Activist Investor, Highlights Strategic Progress and Shareholder Returns
Sentiment: Neutral
View Wiseek Article
PCRX
Mar 11, 2026, 3:25 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement & Formal Sale Process for Pacira BioSciences
Sentiment: Negative
View Wiseek Article
PCRX
Mar 11, 2026, 1:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Activist Investor Demands Pacira CEO Replacement, Cites IP Battle Risks
Sentiment: Negative
View Wiseek Article
PCRX
Feb 26, 2026, 4:16 PM EST
Filing Type: 10-K
Importance Score:
9
Pacira BioSciences Returns to Profitability in 2025 with Strong Revenue Growth and Strategic Progress
Sentiment: Positive
View Wiseek Article
PCRX
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
9
Pacira BioSciences Reports Strong 2025 Turnaround, Significant Share Repurchases, and Positive 2026 Outlook
Sentiment: Positive
View Wiseek Article
PCRX
Jan 28, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Pacira BioSciences Appoints Dr. Samit Hirawat to Board Amidst Activist Investor Pressure
Sentiment: Positive
View Wiseek Article